Keratoconus is a corneal disease that occurs when the normally round shaped cornea progressively thins, causing a cone-like bulge to develop. Patients affected by the condition experience reduced visual acuity, with symptoms worsening as the disease progresses. "Patients with keratoconus have long suffered the devastating affects of the condition. Until now their treatment options have been limited to minimizing the symptoms, but not stopping the progression of the disease. Vance Thompson Vision is delighted to now have the technology to provide a solution to patients affected by this condition," says Dr. John Berdahl, Corneal, Cataract, and Glaucoma surgeon at Vance Thompson Vision who also participated in the clinical trial. "To date, this technology is the only viable option that has the ability to slow or even stop the progression of the disease."
Now that the technology is FDA approved patients have access to the technology. Patients can call Vance Thompson Vision to schedule a consultation to determine if corneal cross-linking is most appropriate option for them. The initial consultation may submitted to insurance.
About Vance Thompson Vision
Vance Thompson Vision, Sioux Falls, SD and Fargo, ND, is a world-class refractive surgery center and research institute. Vance Thompson Vision provides and participates in developing the world's most exceptional technologies to improve outcomes in surgical care; all while creating a patient experience that is second to none. With more than 100,000 procedures, more than 80 FDA monitored clinical trials, and having traveled the world to advance the learning of providers everywhere, Vance Thompson Vision is the standard in quality and innovation. For more information on the international reputation of the doctors that lead studies such as this one visit the biographies of Dr. Vance Thompson, Dr. Alison Tendler, Dr. John Berdahl, Dr. Michael Greenwood, Dr. Doug Wallin, Dr. Keith Rasmussen, Dr. Justin Schweitzer, Dr. Jason Schmit, and Dr. Mitch Ibach.
CEO: Sioux Falls, SD
(605) 371-7120 / firstname.lastname@example.org
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/vance-thompson-vision-contributes-to-fda-approval-of-corneal-crosslinking-for-treating-keratoconus-300341257.html
SOURCE Vance Thompson Vision